Compare Medtronic PLC (MDT) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs 22nd Century Group Inc — how do they compare? Medtronic PLC trades at $82.63 (market cap $106.61B), while 22nd Century Group Inc trades at $4.48 (market cap $1.49M). The key difference: Medtronic PLC is far larger — about 71550.3× 22nd Century Group Inc's market cap, and Medtronic PLC pays a 3.46% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals.
| MDT | XXII | |
|---|---|---|
Market Cap | $106.61B | $1.49M |
Sector | Health | Technology |
52-Week High | $105.35 | $1.07K |
52-Week Low | $73.75 | $3.90 |
Enterprise Value | $125.36B | -$6.74M |
Dividend Yield | 3.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $82.35, down 1.02% on the day, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS expected at $1.39. Revenue grew to $33.54B in 2025, with a net income margin of 13.2%. Recent news highlights the acquisition of SPR and the launch of AI-powered surgical technology, signaling innovation-driven growth.
The outlook for MDT is positive, supported by analyst consensus with a $97.50 price target and 58% buy ratings. Key opportunities include robust cash flow and dividend stability, while risks involve rising debt levels and competitive pressures in medtech. The stock presents a value proposition with a P/E of 22.33, trading below the consensus target.
XXII trades at $4.32, down 0.23% on the day, with neutral technical signals and bearish moving averages. The company shows significant financial challenges with negative profit margins (-65.76% net income margin) and declining revenue, though analyst sentiment remains positive with 75% buy ratings. Recent corporate actions include a 20:1 reverse stock split completed in June 2026, while expansion initiatives in California and New York aim to drive VLN brand growth.
The outlook remains speculative with high execution risk given persistent losses and negative ROE (-130.19%). Investment opportunity hinges on successful commercialization of reduced-nicotine products and FDA regulatory progress, but substantial financial deterioration and competitive pressures present significant downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
